Background Lupus patient’s expectations are no different than everyone else’s: ‘A better life’. But achieving it requires different steps because it entails (1) A prompt diagnosis, (2) Access to ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...

Background Physician-based assessment of SLE activity and damage may not be able to capture the real disease impact on patients life. Objective of our study was to investigate the role of disease ...

The significant allelic effect at rs13385731 and enhancer effect on RasGrp3 expression level. (A) ChIP-qPCR assays for determining allele-specific DNA-protein interactions with H3K27ac, H3K4me1, ...

Objective The heterogeneity of lupus clinical manifestations makes it difficult to precisely characterize the full spectrum of patient profiles with traditional real-life (claims) data sources. This ...

Background Proliferative lupus nephritis (LN) is characterized by robust glomerular and tubulo- interstitial inflammation, sub-endothelial deposits of immunoglobulin, and increased endothelial cell ...

Methods BI 705564 has been studied in 43 male healthy volunteers (HV) in a single-blinded, partially randomized, placebo-controlled trial testing single rising doses from 10 to 160 mg. In a ...

Background People with SLE (and their doctors) are concerned about the risk of COVID-19 infection, yet some patients still harbor concerns regarding vaccination. The first mRNA SARS-CoV-2 vaccines ...

Several questions about SLE pathogenesis have continued to puzzle investigators over decades.A major question in the pathogenesis of SLE is the role of self-antigen. Early studies suggested that SLE ...

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.

Patients with antiphospholipid antibodies (aPL) are at increased risk for arterial or venous thrombosis. There is, however, significant heterogeneity among patients according to clinical and ...

Background SLE may be stratified according to a range of different immune assessments but the relationships between these are less well defined. MASTERPLANS is an MRC-funded consortium that seeks to ...